Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 47 h ago

Sagimet Biosciences Inc.: Woodline Partners LP discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Woodline Partners LP disclosed a stake exceeding 5% in Sagimet Biosciences Inc. via a Schedule 13G filing with the SEC (accession 0000919574-26-008060). The exact share count and percentage were not specified in the filing headline. The disclosure signals a significant institutional position in the clinical-stage biopharmaceutical company. Investors will watch for further detail on the size and intent of the holding, and for any subsequent 13G amendments.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Woodline Partners LP, Sagimet Biosciences Inc.